Lucid Registry Study (Lucid Registry)
A Multicenter, Prospective, Open-Label Registry Study of the Utilization of EsoGuard, on Samples Collected Using EsoCheck, in an At-Risk Population Undergoing Standard of Care Screening for, and Management of, Previously Undiagnosed Barrett's Esophagus and/or Esophageal Adenocarcinoma
Sponsor: Lucid Diagnostics, Inc.
A observational or N/A phase clinical study on Barrett Esophagus and Barrett's Esophagus Without Dysplasia, this trial is ongoing. The trial is conducted by Lucid Diagnostics, Inc. and has accumulated 4 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
4 versions recorded-
Aug 2025 — Present [monthly]
Unknown
Status: Recruiting → Unknown
-
Sep 2024 — Aug 2025 [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
-
Aug 2023 — Jul 2024 [monthly]
Recruiting
First recorded
Apr 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Lucid Diagnostics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .